N/A
Completed N=901
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)
Hepatitis C, Chronic · Hepatitis C
Source: ClinicalTrials.gov NCT00723632 ↗
Enrolled (actual)
901
Serious AEs
—
Results posted
Dec 2011
Primary outcomePrimary: Average Cost Per Participant With Sustained Virologic Response (SVR) Stratified by Weight Category — 28,271; 31,429; 34,782 Czech Crown
Summary
The objective of the study is to evaluate the costs associated with peginterferon alfa-2b (PegIntron) plus ribavirin (Rebetol) treatment for chronic hepatitis C in the Czech Republic. Only costs associated with rescue medication, concomitant therapy, disease monitoring, and medical intervention costs recognized by the treating institution as treatment-related expenses will be included in the analysis. The study will also evaluate the correlation between hepatitis C virus (HCV) therapy-related costs with ribavirin dosing and participant history.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Cost Per Participant With Sustained Virologic Response (SVR) Stratified by Weight Category |
28,271; 31,429; 34,782 | — |
| SECONDARY Average Cost Per Participant With SVR Stratified by Ribavirin Dosage |
31,119; 29,306; 35,621 | — |
| SECONDARY Average Cost Per Participant With SVR Stratified by Prior Treatment Status |
30,109; 37,486 | — |
Eligibility Criteria
Inclusion Criteria
- Participants with chronic hepatitis C
- At least 18 years old
- Eligibility determined based on the diagnosis and medical judgment only.
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT00723632). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.